Published in Vaccine Weekly, April 18th, 2001
Until further studies are conducted to determine its cost-effectiveness and to standardize protocols, oseltamivir's widespread use for influenza B cannot yet be justified, say researchers working in British Columbia.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly